Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Core Insights - VolitionRx Limited presents two studies at the European Lung Cancer Congress 2025, highlighting the potential of its Nu.Q® H3K27Me3 biomarker combined with circulating tumor DNA to enhance prognostic value for overall survival in Non-Small Cell Lung Cancer (NSCLC) [1] - The studies also showcase Volition's Nu.Q® H3.1, a low-cost immunoassay aimed at early identification of individuals at high risk for cancer [1] Group 1: Event Details - The European Lung Cancer Congress 2025 (ELCC 2025) is held in Paris, France from March 26-29, 2025 [2] - Two poster sessions are scheduled for March 28, 2025, featuring presentations on early detection and prognostic biomarkers in NSCLC [3] Group 2: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancer [4] - The company aims to develop cost-effective blood tests to enhance patient outcomes and quality of life through early detection [5] - Volition's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [6]